Johnson & Johnson (JNJ)
NYSE · Healthcare · Drug Manufacturers - General
Profile
Johnson & Johnson
- Exchange
- NYSE
- Ticker
- JNJ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- US
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Key facts
Johnson & Johnson: key facts
- Johnson & Johnson (NYSE: JNJ) is a Drug Manufacturers - General company in the Healthcare sector.
- In fiscal 2025, Johnson & Johnson reported revenue of $94.2B and net income of $26.8B.
- Revenue grew 4.6% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $99.3B and net income was $16.1B.
MonkScore
Johnson & Johnson's MonkScore
MonkScore
MonkScore range: 70–80
as of October 2026
Sector rank: 175 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth20–30
- Profitability70–80
- Quality40–50
- Market Conviction90–100
- Safety80–90
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Johnson & Johnson's annual figures and the last twelve months, in USD. Last report: 27 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $99.3B | $94.2B | $88.8B | $85.2B | $80.0B | $78.7B |
| Gross profit | $68.4B | $63.9B | $61.4B | $58.6B | $55.4B | $55.3B |
| Operating income | $25.5B | $25.6B | $22.1B | $23.4B | $21.0B | $20.9B |
| Net income | $16.1B | $26.8B | $14.1B | $35.2B | $17.9B | $20.9B |
| Operating cash flow | $26.2B | $24.5B | $24.3B | $22.8B | $21.2B | $23.4B |
| Capital expenditure | -$5.6B | -$4.8B | -$4.4B | -$4.5B | -$4.0B | -$3.7B |
| Free cash flow | $20.6B | $19.7B | $19.8B | $18.2B | $17.2B | $19.8B |
| Total debt | $44.7B | $47.9B | $36.6B | $29.3B | $39.6B | $33.8B |
| Cash | $16.9B | $19.7B | $24.1B | $21.9B | $12.9B | $14.5B |
Revenue growth a year
- 1-year
- 6.0%
- 3-year
- 5.6%
- 4-year
- 4.6%
Compound growth between fiscal years.
Peers
Similar companies
- Bristol-Myers Squibb CompanyNYSE:BMYMonkScore range: 80–90
- Amgen Inc.NASDAQ:AMGNMonkScore range: 90–100
- AbbVie Inc.NYSE:ABBVMonkScore range: 90–100
- Gilead Sciences, Inc.NASDAQ:GILDMonkScore range: 90–100
- Eli Lilly and CompanyNYSE:LLYMonkScore range: 90–100
Compare
Compare with
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
Free tools for Johnson & Johnson: Dividend calculator
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.